The DOI matches its Crossref record, with a small difference in title or year; 21 of the 21 references it cites were found in a registry or an index.
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Open accessAbstract
This study investigated the effect of subcutaneously administered oxyntomodulin on body weight in healthy overweight and obese volunteers. Participants self-administered saline or oxyntomodulin subcutaneously in a randomized, double-blind, parallel-group protocol. Injections were self-administered for 4 weeks, three times daily, 30 min before each meal. The volunteers were asked to maintain their regular diet and level of physical exercise during the study period. Subjects’ body weight, energy intake, and levels of adipose hormones were assessed at the start and end of the study. Body weight was reduced by 2.3 ± 0.4 kg in the treatment group over the study period compared with 0.5 ± 0.5 kg in the control group (P = 0.0106). On average, the treatment group had an additional 0.45-kg weight loss per week. The treatment group demonstrated a reduction in leptin and an increase in adiponectin. Energy intake by the treatment group was significantly reduced by 170 ± 37 kcal (25 ± 5%) at the initial study meal (P = 0.0007) and by 250 ± 63 kcal (35 ± 9%) at the final study meal (P = 0.0023), with no change in subjective food palatability. Oxyntomodulin treatment resulted in weight loss and a change in the levels of adipose hormones consistent with a loss of adipose tissue. The anorectic effect was maintained over the 4-week period. Oxyntomodulin represents a potential therapy for obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Oxyntomodulin activates the glucagon receptor and GLP-1 receptor and promotes weight loss through elevated energy expenditure and decreased energy intake in humans (Wynne et al, 2005(Wynne et al, , 2006)).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Wynne et al, 2005
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.
Hedley, A. A., Ogden, C., Johnson, C. L., Carroll, M., Curtin, L. R., & Flegal, K. (2004) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.291.23.2847 · Cited by 4,670
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494
Self-citationGut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Self-citationGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Self-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Food Fails to Suppress Ghrelin Levels in Obese Humans
English, P., Ghatei, M. A., Malik, I., Bloom, S. R., & Wilding, J. P. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8738 · Cited by 535
Self-citationOxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 475
Self-citation
Cited by
Sorted by citations
Items 101–200 of 437
Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Koliaki, C. C., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00396-9 · Cited by 87
Cancer's sweet tooth: the Janus effect of glucose metabolism in tumorigenesis
Ashrafian, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68228-7 · Cited by 79
Buhmann, H., le Roux, C. W., & Bueter, M. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.003 · Cited by 81
Gut Hormones and Energy Balance, The Future for Obesity Therapy?
Meiliana, A., & Wijaya, A. (2009) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v1i3.99 · Cited by 79
The Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2)
Weston, C. A., Lu, J. N., Li, N., Barkan, K., Richards, G. O., Roberts, D. J., Skerry, T. M., Poyner, D. R., Pardamwar, M., Reynolds, C. A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624601 · Cited by 76
Ambery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13688 · Cited by 75
Present and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 81
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 77
CNS-targets in control of energy and glucose homeostasis
Kleinridders, A., Könner, A. C., & Brüning, J. C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.006 · Cited by 74
Theilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 74
Ali, S., Ussher, J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., & Drucker, D. J. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.11.005 · Cited by 69
Can Gut Hormones Control Appetite and Prevent Obesity?
Chaudhri, O. B., Wynne, K., & Bloom, S. R. (2008) · Diabetes Care · doi:10.2337/dc08-s269 · Cited by 71
Self-citationDo Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
Papamargaritis, D., & le Roux, C. W. (2021) · Nutrients · doi:10.3390/nu13030762 · Cited by 68
Mechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity
Vincent, R. P., Ashrafian, H., & le Roux, C. W. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1118 · Cited by 71
Singh, R. G., Nguyen, N. N., DeSouza, S. V., Pendharkar, S. A., & Petrov, M. S. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13523 · Cited by 68
New and Emerging Drug Molecules Against Obesity
George, M., Rajaram, M., & Shanmugam, E. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501017 · Cited by 68
Nielsen, M. S., Ritz, C., Wewer Albrechtsen, N. J., Holst, J. J., le Roux, C. W., & Sjödin, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa061 · Cited by 65
DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives
Santoprete, A., Capitò, E., Carrington, P. E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., et al. (2011) · Journal of Peptide Science · doi:10.1002/psc.1328 · Cited by 65
Obesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 64
Self-citationPeripheral signalling involved in energy homeostasis control
Lancha, A., Frühbeck, G., & Gómez‐Ambrosi, J. (2012) · Nutrition Research Reviews · doi:10.1017/s0954422412000145 · Cited by 66
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease
Glotfelty, E. J., Olson, L., Karlsson, T. E., Li, Y., & Greig, N. H. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764534 · Cited by 63
Martinou, E., Stefanova, I., Iosif, E., & Angelidi, A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063339 · Cited by 64
The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes
Adamska-Patruno, E., Ostrowska, L., Górska, M., & Kretowski, A. J. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.42498 · Cited by 60
Obesity, Gut Hormones, and Bariatric Surgery
Pournaras, D. J., & le Roux, C. W. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0080-9 · Cited by 58
Irwin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i15.1285 · Cited by 61
Treatment of Obesity in Mitigating Metabolic Risk
Heffron, S. P., Parham, J. S., Pendse, J., & Alemán, J. O. (2020) · Circulation Research · doi:10.1161/circresaha.119.315897 · Cited by 62
Sowden, G. L., Drucker, D. J., Weinshenker, D., & Swoap, S. J. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00405.2006 · Cited by 58
Effects of Exercise on Appetite and Food Intake Regulation
Bilski, J., Teległów, A., Zahradnik-Bilska, J., DEMBINSKI, A. B., & Warzecha, Z. (2009) · Medicina Sportiva · doi:10.2478/v10036-009-0014-5 · Cited by 56
Shankar, S. S., Shankar, R. R., Mixson, L. A., Miller, D. L., Pramanik, B., O’Dowd, A. K., Williams, D. M., Frederick, C. B., Beals, C. R., Stoch, S. A., et al. (2018) · Diabetes · doi:10.2337/db17-1331 · Cited by 56
Investigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast
Weston, C. J., Poyner, D. R., Patel, V. C., Dowell, S. J., & Ladds, G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12716 · Cited by 56
Problem or solution: The strange story of glucagon
Scott, R., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.013 · Cited by 60
Self-citationHolst, J. J., Albrechtsen, N. J. W., ROSENKILDE, M. M., & Deacon, C. F. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180013 · Cited by 72
Gastrointestinal hormones, energy balance and bariatric surgery
Bueter, M., & le Roux, C. W. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.146 · Cited by 53
Gastrointestinal satiety signals
Chaudhri, O. B., Field, B. C. T., & Bloom, S. R. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.235 · Cited by 57
Self-citationAtay, Z., & Bereket, A. (2016) · Obesity Medicine · doi:10.1016/j.obmed.2016.05.005 · Cited by 55
Regulation of food intake by gastrointestinal hormones
Baynes, K., Dhillo, W. S., & Bloom, S. R. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000245537.43142.63 · Cited by 53
Self-citationAbnormal rectal endocrine cells in patients with irritable bowel syndrome
El‐Salhy, M., Gundersen, D., Hatlebakk, J. G., Gilja, O. H., & Hausken, T. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.11.005 · Cited by 52
Differential effects of oxyntomodulin and GLP-1 on glucose metabolism
Du, X., Kosinski, J. R., Lao, J. Z., Shen, X., Petrov, A., Chicchi, G. G., Eiermann, G. J., & Pocai, A. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00142.2012 · Cited by 52
The Role of Gut–brain Axis in Regulating Glucose Metabolism After Acute Pancreatitis
Pendharkar, S. A., Asrani, V. M., Murphy, R., Cutfield, R. G., Windsor, J. A., & Petrov, M. S. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.63 · Cited by 52
Long, R. T., Zeng, W., Chen, L. Y., Guo, J., Lin, Y., Huang, Q., & Luo, S. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.277 · Cited by 51
Is the Brain a Key Player in Glucose Regulation and Development of Type 2 Diabetes?
Lundqvist, M., Almby, K. E., Abrahamsson, N., & Eriksson, J. W. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00457 · Cited by 55
Gut Hormones: A Weight Off Your Mind
Gardiner, J., Jayasena, C. N., & Bloom, S. R. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01729.x · Cited by 49
Self-citationOxyntomodulin analogue increases energy expenditure via the glucagon receptor
Scott, R., MINNION, J. S., Tan, T., & Bloom, S. R. (2018) · Peptides · doi:10.1016/j.peptides.2018.04.008 · Cited by 50
Self-citationSubcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents
Liu, Y. ‐., Ford, H. E., Druce, M. R., MINNION, J. S., Field, B. C. T., Shillito, J. C., Baxter, J. E., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.110 · Cited by 48
Self-citationAddressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Mittermayer, F., Caveney, E. J., OLIVEIRA, C. D. F., Gourgiotis, L., Puri, M., Tai, L.-J., & Turner, J. R. (2015) · Current Diabetes Reviews · doi:10.2174/1573399810666141224121927 · Cited by 48
Regulation of appetite to treat obesity
Kim, G. W., Lin, J. E., Valentino, M. A., Colón‐González, F., & Waldman, S. A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.3 · Cited by 46
Old Paradoxes and New Opportunities for Appetite Control in Obesity
Montégut, L., López-Otín, C., Magnan, C., & Kroemer, G. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.005 · Cited by 48
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 45
The role of pancreatic polypeptide in the regulation of energy homeostasis
Khandekar, N., Berning, B. A., Sainsbury, A., & Lin, S. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.028 · Cited by 51
Neuroendocrine Control of Food Intake
Butler, A. A., Trevaskis, J. L., & Morrison, C. D. (2007) · Springer eBooks · doi:10.1007/978-0-387-32164-6_1 · Cited by 44
Bariatric Embolization of the Gastric Arteries for the Treatment of Obesity
Weiss, C. R., Gunn, A. J., Kim, C., Paxton, B. E., Kraitchman, D. L., & Arepally, A. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2015.01.017 · Cited by 45
Michalakis, K. G., & le Roux, C. W. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0698-9 · Cited by 44
Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly
Ouberai, M. M., dos Santos, A. L. G., Kinna, S., Madalli, S., Hornigold, D. C., Baker, D., Naylor, J., Sheldrake, L., Corkill, D. J., Hood, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01114-1 · Cited by 43
Peptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2021) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 50
Elvert, R., Herling, A. W., Bossart, M., Weiss, T., Zhang, B., Wenski, P., Wandschneider, J., Kleutsch, S., Butty, U., Kannt, A., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13212 · Cited by 42
Bianchi, E., Carrington, P. E., Ingallinella, P., Finotto, M., Santoprete, A., Petrov, A., Eiermann, G. J., Kosinski, J. R., Marsh, D. J., Pocai, A., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.016 · Cited by 41
Enteroendocrine hormone mimetics for the treatment of obesity and diabetes
Irwin, N., & Flatt, P. R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.009 · Cited by 41
Xanthakos, S. A. (2008) · Pathophysiology · doi:10.1016/j.pathophys.2008.04.005 · Cited by 41
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 44
New Targets for Drug Treatment of Obesity
Valsamakis, G., Konstantakou, P., & Mastorakos, G. P. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104735 · Cited by 41
Emerging Concepts in the Medical and Surgical Treatment of Obesity
Aylwin, S. J. B., & Al-Zaman, Y. (2008) · Frontiers of hormone research · doi:10.1159/000115368 · Cited by 41
Hartstra, A. V., Nieuwdorp, M., & Herrema, H. (2016) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.08.009 · Cited by 39
Vidarsdóttir, S., Roelfsema, F., Streefland, T. C. M., Holst, J. J., Rehfeld, J. F., & Pijl, H. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0433 · Cited by 37
Simonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264974 · Cited by 36
Bowels control brain: gut hormones and obesity
Bewick, G. A. (2012) · Biochemia Medica · doi:10.11613/bm.2012.032 · Cited by 36
El‐Salhy, M., Gilja, O. H., Gundersen, D., Hatlebakk, J. G., & Hausken, T. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1811 · Cited by 36
Treatment strategies for obesity
Wilding, J. P. H. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00333.x · Cited by 36
Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1
Tharakan, G., Tan, T., & Bloom, S. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.10.003 · Cited by 36
Self-citationGastrointestinal hormones and their role in obesity
Choudhury, S., Tan, T., & Bloom, S. R. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000216 · Cited by 35
Self-citationA novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice
Ma, T., Huo, S., Xu, B., Li, F., Wang, P., Liu, Y., & Lei, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112496 · Cited by 35
Zouhal, H., Sellami, M., Saeidi, A., Slimani, M., Abbassi-Daloii, A., Khodamoradi, A., El Hage, R., Hackney, A. C., & Ben Abderrahman, A. (2019) · Nutrition Reviews · doi:10.1093/nutrit/nuz005 · Cited by 35
Abegg, K., Schiesser, M., Lutz, T. A., & Bueter, M. (2013) · Physiology & Behavior · doi:10.1016/j.physbeh.2013.03.027 · Cited by 34
Oxyntomodulin increases intrinsic heart rate through the glucagon receptor
Mukharji, A., Drucker, D. J., Charron, M. J., & Swoap, S. J. (2013) · Physiological Reports · doi:10.1002/phy2.112 · Cited by 34
The forgotten members of the glucagon family.
Bataille, D., & Dalle, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.06.010 · Cited by 37
Hage, M. P., Safadi, B. Y., Salti, I., & Nasrallah, M. (2012) · ISRN Endocrinology · doi:10.5402/2012/504756 · Cited by 35
Modulatory role of serotonin on feeding behavior
Magalhães, C. P., de Freitas, M. F. L., Nogueira, M. I., Campina, R. C. D. F., Takase, L. F., de Souza, S. L., & Manhães‐de‐Castro, R. (2010) · Nutritional Neuroscience · doi:10.1179/147683010x12611460764723 · Cited by 32
Gut hormones: the future of obesity treatment?
McGavigan, A. K., & Murphy, K. G. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04278.x · Cited by 31
Self-citationRole of Gut Hormones in Obesity
Jayasena, C. N., & Bloom, S. R. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.07.001 · Cited by 32
Self-citationGut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 33
Self-citationPharmacological Treatment of Obesity
Kabra, D. G., Kabra, U. D., Tschöp, M. H., & Hofmann, S. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3492-4_14 · Cited by 32
Perugini, R. A., & Malkani, S. (2011) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283446c1f · Cited by 31
Castagneto‐Gissey, L., Mariolo, J. R. C., & Mingrone, G. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.010 · Cited by 32
Riediger, T., Eisele, N., Scheel, C., & Lutz, T. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00438.2009 · Cited by 29
Corbin, K. D., Carnero, E. A., Allerton, T. D., Tillner, J., Bock, C. P., Luyet, P., Göbel, B., Hall, K. D., Parsons, S. A., Ravussin, E., et al. (2023) · Obesity · doi:10.1002/oby.23633 · Cited by 32
Shah, A., Dodson, W. C., Kris‐Etherton, P. M., Kunselman, A. R., Stetter, C., Gnatuk, C. L., Estes, S. J., Allison, K. C., Sarwer, D. B., Sluss, P. M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa682 · Cited by 30
Interaction between diet and gastrointestinal endocrine cells
El‐Salhy, M., Mazzawi, T. R. E., Hausken, T., & Hatlebakk, J. G. (2016) · Biomedical Reports · doi:10.3892/br.2016.649 · Cited by 30
Role of gastrointestinal hormones in feeding behavior and obesity treatment
Kairupan, T. S., Amitani, H., Cheng, K., Runtuwene, J., Asakawa, A., & Inui, A. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1118-4 · Cited by 29
Pimentel, G. D., Mota, J. F., & Oyama, L. M. (2009) · Revista de Nutrição · doi:10.1590/s1415-52732009000500013 · Cited by 29
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 28
Obesity Pharmacotherapy: Current Perspectives and Future Directions
Misra, M. (2013) · Current Cardiology Reviews · doi:10.2174/157340313805076322 · Cited by 29
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 31
Self-citationNogueiras, R. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0277 · Cited by 29
Glucagon receptor signaling in metabolic diseases
Albrechtsen, N. J. W. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.016 · Cited by 28
Gastrointestinal peptides controlling body weight homeostasis
Zerón, H. M., López, M., & Diéguez, C. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.11.009 · Cited by 29
Investigational therapies in the treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.897 · Cited by 28
National survey of pediatric fever management practices among emergency department nurses.
Thomas, V., Riegel, B. J., Andrea, J., Murray, P., Gerhart, A. E., & Gocka, I. (1994) · PubMed · Cited by 27
Metadata
- Authors
- Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Hammersmith Hospital (GB)
- Department of Dietetics, Imperial College Faculty of Medicine, Hammersmith Hospital, London, U.K
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2005-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 2390-2395
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2154497567
- Cited by
- 435
- References
- 21
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 17 · 2023: 24 · 2022: 10 · 2021: 24 · 2020: 22 · 2019: 16 · 2018: 26 · 2017: 17 · 2016: 20 · 2015: 24 · 2014: 22 · 2013: 31 · 2012: 26
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- oxyntomodulin, obesity, weight loss, subcutaneous administration, energy intake, leptin, adiponectin, adipose tissue, anorectic effect, palatability, appetite regulation
- MeSH terms
- Adipose Tissue, Adolescent, Adult, Blood Glucose, Body Composition, Energy Intake, Diet, Double-Blind Method, Eating, Glucagon-Like Peptides, Female, Humans, Injections, Subcutaneous, Insulin, Kinetics, Male, Middle Aged, Obesity, Self Administration, Weight Loss, Exercise, Leptin, Intercellular Signaling Peptides and Proteins, Adiponectin, Oxyntomodulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
